Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
<h4>Objectives</h4>Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0268780&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849704942162411520 |
|---|---|
| author | Michaela Bitzenhofer Franziska Suter-Riniker Matthias B Moor Daniel Sidler Michael P Horn Anna Gschwend Cornelia Staehelin Andri Rauch Arthur Helbling Lukas Jörg |
| author_facet | Michaela Bitzenhofer Franziska Suter-Riniker Matthias B Moor Daniel Sidler Michael P Horn Anna Gschwend Cornelia Staehelin Andri Rauch Arthur Helbling Lukas Jörg |
| author_sort | Michaela Bitzenhofer |
| collection | DOAJ |
| description | <h4>Objectives</h4>Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral immune response after two vaccine doses with BNT162b2 or mRNA-1273 in patients with humoral immunodeficiency disease.<h4>Methods</h4>This cross-sectional study assessed 39 individuals with hypogammaglobulinemia under immunoglobulin replacement therapy. IgG anti-SARS-CoV-2 spike protein antibodies (anti-S) were measured 4 weeks to 4 months after two doses of an mRNA vaccine against SARS-CoV-2. The proportion of patients, who developed a humoral immune response to the spike protein were evaluated and compared to 19 healthy controls.<h4>Results</h4>After vaccination with two vaccine doses, 26/39 patients (66.7%) with humoral immunodeficiency disease and all healthy controls developed anti-S. In subjects with baseline IgG <3 g/l, only 1/5 (20%) showed a humoral immune response. 10 out of 26 with CVID (38.5%) and 7/9 under immunosuppressive drugs (77.8%) developed no immune response (13 subjects with no response) compared to 0/19 in healthy controls. Subgroup analysis in patients without immunosuppressive drugs revealed lower anti-S in patients with moderate to severe humoral immunodeficiency disease: baseline IgG <3 g/l: 12.0 AU/ml (95%CI 12.0-125.0), baseline IgG 3-5 g/l: 99.9 AU/ml (95%CI 14.4-400.0), baseline IgG >5 g/l: 151.5 AU/ml (95%CI 109.0-400.0), healthy controls 250.0 AU/ml (95%CI 209.0-358.0), p = 0.007.<h4>Conclusion</h4>In most patients with mild to moderate humoral immunodeficiency we found only slightly lower anti-S antibodies compared with healthy controls after two vaccine doses with BNT162b2 and mRNA-1273. However, in patients with a decreased baseline IgG below 3 g/l and/or under immunosuppressive drugs, we found severely impaired humoral immune responses. |
| format | Article |
| id | doaj-art-b2a5f262276d4a26a74b0d1b03d465c0 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-b2a5f262276d4a26a74b0d1b03d465c02025-08-20T03:16:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01176e026878010.1371/journal.pone.0268780Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.Michaela BitzenhoferFranziska Suter-RinikerMatthias B MoorDaniel SidlerMichael P HornAnna GschwendCornelia StaehelinAndri RauchArthur HelblingLukas Jörg<h4>Objectives</h4>Although mRNA-based vaccines against SARS-CoV-2 induce a robust immune response and prevent infections and hospitalizations, there are limited data on the antibody response in individuals with humoral immunodeficiency. The aim of this study was to evaluate the humoral immune response after two vaccine doses with BNT162b2 or mRNA-1273 in patients with humoral immunodeficiency disease.<h4>Methods</h4>This cross-sectional study assessed 39 individuals with hypogammaglobulinemia under immunoglobulin replacement therapy. IgG anti-SARS-CoV-2 spike protein antibodies (anti-S) were measured 4 weeks to 4 months after two doses of an mRNA vaccine against SARS-CoV-2. The proportion of patients, who developed a humoral immune response to the spike protein were evaluated and compared to 19 healthy controls.<h4>Results</h4>After vaccination with two vaccine doses, 26/39 patients (66.7%) with humoral immunodeficiency disease and all healthy controls developed anti-S. In subjects with baseline IgG <3 g/l, only 1/5 (20%) showed a humoral immune response. 10 out of 26 with CVID (38.5%) and 7/9 under immunosuppressive drugs (77.8%) developed no immune response (13 subjects with no response) compared to 0/19 in healthy controls. Subgroup analysis in patients without immunosuppressive drugs revealed lower anti-S in patients with moderate to severe humoral immunodeficiency disease: baseline IgG <3 g/l: 12.0 AU/ml (95%CI 12.0-125.0), baseline IgG 3-5 g/l: 99.9 AU/ml (95%CI 14.4-400.0), baseline IgG >5 g/l: 151.5 AU/ml (95%CI 109.0-400.0), healthy controls 250.0 AU/ml (95%CI 209.0-358.0), p = 0.007.<h4>Conclusion</h4>In most patients with mild to moderate humoral immunodeficiency we found only slightly lower anti-S antibodies compared with healthy controls after two vaccine doses with BNT162b2 and mRNA-1273. However, in patients with a decreased baseline IgG below 3 g/l and/or under immunosuppressive drugs, we found severely impaired humoral immune responses.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0268780&type=printable |
| spellingShingle | Michaela Bitzenhofer Franziska Suter-Riniker Matthias B Moor Daniel Sidler Michael P Horn Anna Gschwend Cornelia Staehelin Andri Rauch Arthur Helbling Lukas Jörg Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. PLoS ONE |
| title | Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. |
| title_full | Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. |
| title_fullStr | Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. |
| title_full_unstemmed | Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. |
| title_short | Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease. |
| title_sort | humoral response to mrna vaccines against sars cov 2 in patients with humoral immunodeficiency disease |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0268780&type=printable |
| work_keys_str_mv | AT michaelabitzenhofer humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT franziskasuterriniker humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT matthiasbmoor humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT danielsidler humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT michaelphorn humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT annagschwend humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT corneliastaehelin humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT andrirauch humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT arthurhelbling humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease AT lukasjorg humoralresponsetomrnavaccinesagainstsarscov2inpatientswithhumoralimmunodeficiencydisease |